Express delivery and free returns within 21 days

Wednesday, June 29, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

FDA Grants Oxehealth Vital Signs De Novo Clearance

Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the vision-based patient monitoring and management platform delivered as software as a service.

- Advertisement -

Chief Executive of the company, Mr. Hugh Lloyd-Jukes said, “Receiving a de novo FDA clearance and creating an entirely new category of medical device is an exceptional achievement for Oxehealth.¬†We are excited that we can now begin partnering with clinicians and the leadership teams of healthcare providers in America to enable them to deliver safer, higher quality and more cost-efficient care.”

Company Chairman James Ede-Golightly said, “Oxevision has supported the provision of over 5 million hours of patient care. Approaching 40% of English Mental Health Trusts rely on Oxevision to support the work of their clinical teams. Our experience in the UK and Swedish markets positions us strongly for success in the US market.”

SourceOxehealth
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
spot_img

Other News of Interest

Executives on the Move

By using this website you agree to accept Medical Device News Magazine Privacy Policy